Women's sexual health after anal cancer radiation
Part of Cancer, Digestive system clinical trials.
This study looks at how women feel about their gynecological and sexual health after finishing radiation therapy for anal cancer. It may help doctors learn how to better support their patients after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with anal cancer.
- You finished chemoradiotherapy (chemo plus radiation) between 6 and 36 months ago.
- You are willing to take part in the study and can give your written permission.
- You have not had radiation therapy to the pelvic area for any other cancer before.
- You can speak and understand Danish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people’s day-to-day functioning and quality of life change after an anal cancer diagnosis. It mainly enrolls adults recently diagnosed to understand outcomes early on.
This study looks at how anal cancer tissue and samples change during and after treatment. Your participation may help doctors understand treatment response, especially for people with newly diagnosed or returning anal cancer.
This study follows women treated for HPV-positive pelvic cancers (cervix, vagina, vulva, or anus) to understand how radiotherapy and surgery affect sexual quality of life. Researchers want to learn about recovery and support needs after treatment.
This trial tests a shorter course of radiation therapy given with chemotherapy for people with high-risk anal cancer. The goal is to see if the shorter treatment is just as effective but causes fewer side effects and is more convenient.
This observational study follows people with anal cancer to understand how their quality of life changes after they receive standard chemoradiation therapy. It may help doctors better support patients with symptoms, recovery, and daily functioning over time.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Hear when a new Anal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.